Coeptis Therapeutics Enters Material Definitive Agreement

Ticker: COEPW · Form: 8-K · Filed: Apr 28, 2025 · CIK: 1759186

Sentiment: neutral

Topics: material-agreement, corporate-action

Related Tickers: COEP

TL;DR

Coeptis Therapeutics (COEP) signed a big deal on 4/25/25. Details to follow.

AI Summary

On April 25, 2025, Coeptis Therapeutics Holdings, Inc. entered into a material definitive agreement. The company, formerly known as Bull Horn Holdings Corp., is incorporated in Delaware and operates in the biological products sector. This filing is a current report under the Securities Exchange Act of 1934.

Why It Matters

This filing indicates a significant new agreement for Coeptis Therapeutics, which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specific nature of this agreement is not detailed in the provided excerpt.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Coeptis Therapeutics Holdings, Inc. on April 25, 2025?

The provided excerpt does not specify the details of the material definitive agreement.

What was Coeptis Therapeutics Holdings, Inc. formerly known as?

Coeptis Therapeutics Holdings, Inc. was formerly known as Bull Horn Holdings Corp.

In which state is Coeptis Therapeutics Holdings, Inc. incorporated?

Coeptis Therapeutics Holdings, Inc. is incorporated in Delaware.

What is the business address of Coeptis Therapeutics Holdings, Inc.?

The business address is 105 Bradford Road, Suite 420, Wexford, PA 15090.

What is the SIC code for Coeptis Therapeutics Holdings, Inc.?

The Standard Industrial Classification (SIC) code is 2836 for Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2025 regarding Coeptis Therapeutics Holdings, Inc. (COEPW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing